Background & Aims : Because the mechanisms leading to bile duct damage in sclerosing
cholangitis are unknown, we aimed to determine the pathogenesis of bile duct injury in …

Reduced hepatobiliary transporter expression could explain impaired hepatic uptake and
excretion of bile salts and other biliary constituents resulting in cholestasis and jaundice. …

Cholestasis results in intrahepatic accumulation of cytotoxic bile acids which cause liver injury
ultimately leading to biliary fibrosis and cirrhosis. Cholestatic liver damage is counteracted …

Induction of hepatic phase I/II detoxification enzymes and alternative excretory pumps may
limit hepatocellular accumulation of toxic biliary compounds in cholestasis. Because the …

Background & Aims: Rifampicin (RIFA) and ursodeoxycholic acid (UDCA) improve symptoms
and biochemical markers of liver injury in cholestatic liver diseases by largely unknown …

Recent progress in basic research has enhanced our understanding of the molecular
mechanisms of normal bile secretion and their alterations in cholestasis. Genetic transporter …

Organic solute transporter (OSTα-OSTβ) is a novel heteromeric bile acid and sterol transporter
expressed at the basolateral membranes of epithelium in the ileum, kidney, and liver. To …

Background & Aims: Current therapy for primary sclerosing cholangitis is of limited efficacy.
Multidrug resistance gene 2 knockout mice (Mdr2 −/− ) represent a well-characterized model …

Background & Aims: The effects of ursodeoxycholic acid (UDCA) in biliary obstruction are
unclear. We aimed to determine the effects of UDCA in bile duct–ligated and in Mdr2 knockout (…

Background/Aims: Information about alterations of hepatobiliary transporter expression in
primary biliary cirrhosis (PBC) could provide important insights into the pathogenesis of …